Literature DB >> 28574930

Use of Adjuvant Chemotherapy, Radiation Therapy, or Combined Modality Therapy and the Impact on Survival for Uterine Carcinosarcoma Limited to the Pelvis.

Andrew T Wong1, Yi-Chun Lee, David Schwartz, Anna Lee, Meng Shao, Peter Han, Kwang Choi, David Schreiber.   

Abstract

OBJECTIVE: Clinical outcomes for patients with uterine carcinosarcoma are poor after surgical management alone. Adjuvant therapies including chemotherapy (CT) and/or radiation therapy (RT) have been previously investigated, but the optimal management of this disease remains controversial. The purposes of this study were to analyze the patterns of use of adjuvant CT and RT and to assess the impact on survival of each of these treatment regimens using the National Cancer Data Base. METHODS/MATERIALS: The National Cancer Data Base was queried for patients given a diagnosis of uterine carcinosarcoma confined to the pelvis who underwent total hysterectomy/bilateral salpingo-oophorectomy between 2004 and 2011. Patients were excluded if they survived less than 4 months after diagnosis. Data regarding CT and RT use were collected. Overall survival (OS) was analyzed using the Kaplan-Meier method. Multivariable Cox regression analysis was performed to evaluate the effect of covariates on OS.
RESULTS: A total of 4906 patients were included in this study. Median age was 67 years (interquartile range, 60-75 years). Median follow-up was 28.9 months (interquartile range, 15.4-52.9 months). There were 1777 patients (36.2%) who received no adjuvant treatment, 971 (19.8%) who received CT alone, 1060 (21.6%) who received RT alone, and 1098 (22.4%) who received both RT and CT. The 5-year OS for patients receiving no adjuvant therapy, adjuvant RT alone, adjuvant CT alone, and combined CT and RT were 44.9%, 47.1%, 47.5%, and 62.9%, respectively. On pairwise analysis, combined CT and RT was associated with improved survival compared with all other subgroups (P < 0.001). On multivariable Cox regression analysis, combined CT and RT (hazard ratio, 0.50; 95% confidence interval, 0.44-0.57; P < 0.001) and CT alone (hazard ratio, 0.78; 95% confidence interval, 0.69-0.88; P < 0.001) were significantly associated with improved OS, whereas RT alone was not.
CONCLUSIONS: Combination therapy with CT and RT was associated with significantly improved 5-year OS compared with no further therapy, RT alone, or CT alone.

Entities:  

Mesh:

Year:  2017        PMID: 28574930     DOI: 10.1097/IGC.0000000000001014

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  3 in total

1.  Hypofractionated Accelerated Chemo-radiotherapy (Chemo-HypoAR) With Cisplatin and Liposomal Doxorubicin for the Treatment of Patients With Uterine Sarcomas.

Authors:  Spyros Domoxoudis; Ioannis M Koukourakis; Axiotis G Giakzidis; Michael I Koukourakis
Journal:  In Vivo       Date:  2019 Sep-Oct       Impact factor: 2.155

2.  Uterine carcinosarcoma: A 10-year single institution experience.

Authors:  Leana Terblanche; Matthys H Botha
Journal:  PLoS One       Date:  2022-07-21       Impact factor: 3.752

3.  Patterns of adjuvant treatment and survival outcomes in stage I uterine carcinosarcoma.

Authors:  Lori Cory; Colleen Brensinger; Robert A Burger; Robert L Giuntoli; Mark A Morgan; Nawar Latif; Lilie L Lin; Emily M Ko
Journal:  Gynecol Oncol Rep       Date:  2022-01-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.